title: Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines.
abstract: We evaluated the capacity of the cationic lipid based formulation, Vaxfectin, to enhance the immunogenicity and protective efficacy of DNA-based vaccine regimens in the Plasmodium yoelii murine malaria model. We immunized Balb/c mice with varying doses (0.4-50 microg) of plasmid DNA (pDNA) encoding the P. yoelii circumsporozoite protein (PyCSP), either in a homologous DNA/DNA regimen (D-D) or a heterologous prime-boost DNA-poxvirus regimen (D-V). At the lowest pDNA doses, Vaxfectin substantially enhanced IFA titers, ELISPOT frequencies, and protective efficacy. Clinical trials of pDNA vaccines have often used low pDNA doses based on a per kilogram weight basis. Formulation of pDNA vaccines in Vaxfectin may improve their potency in human clinical trials.
authors.affiliation: Malaria Program, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500, USA. sedegahm@mmrc.navy.mil
authors.forename: Martha
authors.initials: M
authors.lastname: Sedegah
authors.forename: William O
authors.initials: WO
authors.lastname: Rogers
authors.forename: Arnel
authors.initials: A
authors.lastname: Belmonte
authors.forename: Maria
authors.initials: M
authors.lastname: Belmonte
authors.forename: Glenna
authors.initials: G
authors.lastname: Banania
authors.forename: Noelle
authors.initials: N
authors.lastname: Patterson
authors.forename: Marilyn
authors.initials: M
authors.lastname: Ferrari
authors.forename: David C
authors.initials: DC
authors.lastname: Kaslow
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Carucci
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Richie
authors.forename: Denise L
authors.initials: DL
authors.lastname: Doolan
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006801:Humans; D007117:Immunization, Secondary; D008214:Lymphocytes / Q000276:immunology; D008288:Malaria / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010714:Phosphatidylethanolamines / Q000008:administration & dosage / Q000494:pharmacology*; D010967:Plasmodium yoelii / Q000276:immunology*; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology*; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014616:Vaccinia virus / Q000235:genetics
chemical_list: D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D017780:Malaria Vaccines; D010714:Phosphatidylethanolamines; D015800:Protozoan Proteins; D019444:Vaccines, DNA; C041595:circumsporozoite protein, Protozoan; C460866:vaxfectin